

CLAIMS

1. Use of a LINE-1 inhibitor, or a pharmaceutical composition thereof, in the manufacture of a medicament for treating or preventing a disease in a subject, wherein the disease is ataxia-telangiectasia, age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,



or


.

2. The use of claim 1, wherein the disease is ataxia-telangiectasia.

3. The use of claim 1, wherein the disease is age-related macular degeneration.

4. The use of claim 1, wherein the disease is systemic lupus erythematosus.

5. The use of claim 1, wherein the disease is IFN-associated autoimmune disease.

6. The use of claim 5, wherein the disease is psoriasis.


7. The use of claim 1, wherein the disease is Fanconi Anemia.

8. The use of claim 1, wherein the disease is idiopathic pulmonary fibrosis.

9. The use of claim 1, wherein the disease is cardiovascular disease.

10. The method of any one of claims 1-9, wherein the LINE-1 inhibitor is censavudine.

11. The method of any one of claims 1-9, wherein the LINE-1 inhibitor is:




12. The use of any one of claims 1-11 for treating the disease.

13. The use of any one of claims 1-11 for preventing the disease.

14. The use of any one of claims 1-13, further comprising administering one or more optional therapeutic agents to the subject.


15. The use of any one of claims 1-14, wherein the subject is (a) not infected with the HIV virus, (b) is not suspected of being infected with the HIV virus, and/or (c) is not being treated to prevent infection with the HIV virus.

16. A kit comprising a LINE-1 inhibitor, or a pharmaceutical composition thereof, and instructions of administering the LINE-1 inhibitor, or pharmaceutical composition thereof, to a subject having a disease, wherein the disease is ataxia-telangiectasia, age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,



17. The kit of claim 16, wherein the LINE-1 inhibitor is censavudine.

18. The kit of claim 16, wherein the LINE-1 inhibitor is:



19. The kit of any one of claims 16-18 further comprising one or more optional therapeutic agents.

20. The kit of any one of claims 16-19, wherein the subject is (a) not infected with the HIV virus, (b) is not suspected of being infected with the HIV virus, and/or (c) is not being treated to prevent infection with the HIV virus.